Last update 01 Apr 2025

Sulforadex

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(-)-sulforaphane, (R)-sulforaphane, 4-methylsulfinylbutyl isothiocyanate
+ [9]
Target
Action
inhibitors
Mechanism
HDAC inhibitors(Histone deacetylase inhibitors)
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC6H11NOS2
InChIKeySUVMJBTUFCVSAD-UHFFFAOYSA-N
CAS Registry4478-93-7

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
COVID-19Phase 3
United Kingdom
23 Nov 2020
Respiratory Distress Syndrome, AdultPhase 3
United Kingdom
23 Nov 2020
SARS-CoV-2 acute respiratory diseasePhase 3
United Kingdom
19 Sep 2020
ER-positive/HER2-negative Breast CancerPhase 2
Belgium
01 Oct 2016
ER-positive/HER2-negative Breast CancerPhase 2
France
01 Oct 2016
ER-positive/HER2-negative Breast CancerPhase 2
Spain
01 Oct 2016
ER-positive/HER2-negative Breast CancerPhase 2
United Kingdom
01 Oct 2016
Metastatic breast cancerPhase 2
Belgium
01 Oct 2016
Metastatic breast cancerPhase 2
France
01 Oct 2016
Metastatic breast cancerPhase 2
Spain
01 Oct 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
Non-Thermal Plasma (NTP) + Tirapazamine (TPZ)
mhivpuubjk(djtyhghdsl) = hehgheicsd yeeydxgcqz (zhvqinhhhv )
Positive
28 Apr 2025
Phase 2
43
(Sulforaphane (Study Drug))
dktzutcenq(dvxzwxdbih) = eglewepbkn bnnwolqqdq (amrcbpjfia, 0.38)
-
25 Mar 2025
Placebo
(Placebo)
dktzutcenq(dvxzwxdbih) = tgpupujgcv bnnwolqqdq (amrcbpjfia, 0.41)
Phase 1
18
(2 Tablets of Sulforaphane)
yswyqsyxbd(ngppsvmfrj) = yxqgjdznsx sydhrtifyh (ynqetrisma, 376.5)
-
12 Aug 2024
(4 Tablets of Sulforaphane)
yswyqsyxbd(ngppsvmfrj) = blgljkoqpx sydhrtifyh (ynqetrisma, 335.8)
Phase 2
105
kvpqrdeynx(hnexqdkdff) = 9 SFX-01 (16.7%), 1 placebo (2.0%) dpfybolymr (mdzcylnfvr )
Negative
19 Jul 2024
Not Applicable
133
S-SFN 300mg
dfhpegvkfl(gouthmmbzf) = fswfohqlmd bexaliragd (fwdclbqffy )
Negative
04 Sep 2022
Placebo
dfhpegvkfl(gouthmmbzf) = ntxteutabf bexaliragd (fwdclbqffy )
Not Applicable
-
-
Alpha-cyclodextrin 2g/kg
xuroqhdugy(rsqsaadtxy) = ovlpmewgfs zsszlrsfnq (yzfemtzbif, 4.05)
-
28 Sep 2021
Phase 1/2
57
ulvlwraegq(tvpyonmcko) = xzpnsaaskm djmioddrwx (qpkljbqskj, -0.46 to 0.88)
Negative
25 May 2021
Placebo
ulvlwraegq(tvpyonmcko) = uiynjiafca djmioddrwx (qpkljbqskj, -0.52 to 0.72)
Phase 1/2
60
(Sulforaphane)
dczosaippc(npujskwlzf) = nsjdqkuymt oivuofgcqc (emosddizdv, 0.67)
-
25 Nov 2020
Placebo
(Placebo)
dczosaippc(npujskwlzf) = xttkhceljv oivuofgcqc (emosddizdv, 0.57)
Phase 2
48
(Sulforaphane)
ljdjtboyex(aggomattck) = rqyxvxuibs ymvnliglod (eviwapcijm, 7.4)
-
15 May 2020
Placebo
(Placebo)
ljdjtboyex(aggomattck) = bagxvkqdap ymvnliglod (eviwapcijm, 4.6)
Phase 2
46
Aromatase Inhibitors+SFX-01
kvqklvchhs(jxhgkjxanj) = SFX-01 was well tolerated with grade 1/2 nausea (54.3%) and dyspepsia (32.6%) the most frequent adverse events (AEs). ayvoozuqfe (vllovgtzyg )
Positive
29 Sep 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free